Advanced Practice

CAR T-cell therapy for children: Meeting patient and family needs

HemOnc Today, January 25, 2020
Amy Barry, MSN, RN, PPCNP-BC; Colleen Callahan, MSN, RN, CRNP; Diane Baniewicz, MSN, RN, CRNP
Chimeric antigen receptor T-cell therapy is a promising immunotherapy for children with refractory or relapsed acute lymphoblastic leukemia who…

Feature

Collaboration to ease clinical trial search process for patients with blood cancers

January 24, 2020
Patients with cancer often feel overwhelmed by the reality of their disease and may struggle simply to maintain the course of treatment set forth by…

In the Journals

Allogeneic HSCT survival outcomes show ‘striking improvement’

January 20, 2020
Patients who received allogeneic hematopoietic stem cell transplants between 2013 and 2017 demonstrated substantial improvement in survival outcomes…

Physicians join John Theurer Cancer Center medical staff

January 18, 2020
John Theurer Cancer Center at Hacksensack University Cancer Center announced the appointment of five physicians to its medical staff.

In the Journals

CT scans linked to higher risk for certain cancers

January 14, 2020
Adults in Taiwan exposed to radiation from CT scans demonstrated increased risk for thyroid cancer and leukemia, according to results of a nested…

Feature

‘Immunotransplant’ shows potential for non-Hodgkin lymphoma

January 13, 2020
A combination of immunotherapy and stem cell transplantation could benefit patients with treatment-resistant non-Hodgkin lymphoma, according to…

Loncastuximab tesirine appears effective for relapsed or refractory DLBCL

January 11, 2020
Loncastuximab tesirine appeared effective and safe for patients with relapsed or refractory diffuse large B-cell lymphoma, according to topline data…

Editorial

Reflections on my 30th ASH Annual Meeting

HemOnc Today, January 10, 2020
John Sweetenham, MD
Since having the good fortune to take on an editorial role for HemOnc Today, I have resisted the temptation to use the January editorial to provide…

In the JournalsPerspective

Cancer mortality rate drops 29% between 1991 and 2017

January 8, 2020
Cancer mortality rates dropped by 29% between 1991 and 2017 in the United States, with a 2.2% drop between 2016 and 2017, according to according to…

FDA News

FDA grants orphan drug designation to CLR 131 for lymphoplasmacytic lymphoma

January 8, 2020
The FDA granted orphan drug designation to CLR 131 for treatment of lymphoplasmacytic lymphoma. CLR 131 (Cellectar Biosciences) is a small-molecule…

Feature

An emerging industry looks to take T cells to the cryobank

December 30, 2019
An increasing body of evidence shows that using younger, less heavily pretreated T cells results in more effective chimeric antigen receptor T-cell…

Meeting NewsPerspective

Dual target CAR T/natural killer cell therapy shows promise for B-cell malignancies

December 27, 2019
ORLANDO — Two major impediments to widespread adoption of chimeric antigen receptor T-cell therapies are their cost and antigen loss that makes…

Meeting NewsPerspective

Mosunetuzumab induces remissions in advanced non-Hodgkin lymphoma after CAR-T fails

December 23, 2019
ORLANDO — About 20% of a cohort of patients with aggressive relapsed or refractory non-Hodgkin lymphoma experienced complete response to…

ASH presents Scholar Awards to fellows, junior faculty

December 22, 2019
ASH announced the recipients of its 2019 Scholar Awards. The awards — presented to hematologists in the United States and Canada who conduct…

Drug Pipeline

Bristol-Myers Squibb seeks FDA biologics license for CAR T-cell therapy in advanced large B-cell lymphoma

December 19, 2019
Bristol-Myers Squibb has submitted a biologics license application to the FDA for the company’s investigational chimeric antigen receptor…

Meeting News

Decisions for patients with IBD, cancer must be made case-by-case

December 17, 2019
ORLANDO — Inflammatory bowel disease is a life-altering condition that takes a lifetime of care. Adding it to another life-altering disease…

Drug Pipeline

Kite submits BLA to FDA for CAR T-cell therapy in mantle cell lymphoma

December 12, 2019
Biopharma company Kite, a subsidiary of Gilead, has submitted a biologics license application to the FDA for the company’s investigational…

Meeting News

Anti-PD-1 therapy after CAR T-cell therapy shows efficacy in Hodgkin lymphoma

December 12, 2019
ORLANDO — Researchers demonstrated the clinical efficacy of anti-PD-1 mAb therapy following treatment with chimeric receptor modified T cells…

Meeting NewsVideo

Early steroid use may reduce CAR T-cell treatment-related toxicity in aggressive lymphoma

December 12, 2019
ORLANDO — Early steroid use appeared to reduce the incidence of severe cytokine release syndrome and neurotoxicity without affecting response…

Meeting News

Novel therapy combination effective in large cell lymphoma

December 12, 2019
ORLANDO – Combining all novel drugs – rituximab, lenalidomide and ibrutinib – to treat diffuse large B-cell lymphoma proved more…